Kết quả bước đầu điều trị osimertinib bước một ở bệnh nhân ung thư phổi không tế bào nhỏ giai đoạn tiến xa có đột biến gen EGFR

Abstract

Background: Osimertinib is currently indicated as first-line treatment for patients with advanced stage non-small cell lung cancer (NSCLC) with EGFR mutations; however, real-world data in Vietnam were limited. The objective of the study was to evaluate the initial results of first-line treatment in patients with advanced NSCLC with EGFR mutations by osimertinib. Subject and method: retrospective study combining prospective and longitudinal follow-up, 54 patients with advanced NSCLC with EGFR mutations were treated with osimertinib as first-line treatment. Patients were followed and assessed for response at 2 months and then every 3 months or when symptoms of disease progression. Primary endpoints were progression-free survival (PFS), objective response rate (ORR), secondary endpoints were disease control rate (DCR) and adverse events. Result: The mean age of patients was 64.07 years, 14 patients had brain metastasis, and 9 patients had uncommon EGFR mutations. ORR was 87.1% with 13% complete response, DCR was 98.1%. Median PFS was 24 months, estimated PFS rates at 1 year, 2 years and 3 years were 68.5%, 47.3% and 25.9%, respectively. There was no statistically significant difference in median PFS between patients with brain metastasis and patients without brain metastasis (24 months for each patient group), p= 0.93. Median PFS in patients with exon 19 deletion mutation was 27 months, while patients with L858R mutation was 19 months and patients with uncommon EGFR mutations was 25 months, p= 0.67. Adverse events occurred in 27.8% of patients, all were grade 1, grade 2. Conclusion: Osimertinib is an effective option and safety in first-line treatment of advanced NSCLC patients with EGFR mutations.